Is rentosertib an approved therapy for idiopathic pulmonary fibrosis, and what is its current clinical trial status?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Rentosertib Status for Idiopathic Pulmonary Fibrosis

Rentosertib is NOT an FDA-approved therapy for idiopathic pulmonary fibrosis and remains investigational. It is a first-in-class AI-generated TNIK inhibitor that has completed only a phase 2a trial, showing preliminary safety and potential efficacy signals but requiring larger confirmatory studies before clinical use 1.

Current Regulatory and Clinical Status

Rentosertib (formerly ISM001-055) has completed a single phase 2a randomized, double-blind, placebo-controlled trial with 71 patients treated for 12 weeks 1. This represents the earliest stage of human efficacy testing—far from regulatory approval.

Phase 2a Trial Results (2025)

Safety Profile:

  • Primary endpoint (treatment-emergent adverse events) was similar across all groups: 72-83% in rentosertib arms versus 71% in placebo 1
  • Treatment-related serious adverse events were low and comparable
  • Most common discontinuation reasons: liver toxicity and diarrhea 1

Efficacy Signals:

  • At the highest dose (60 mg once daily), forced vital capacity increased by +98.4 ml (95% CI: 10.9 to 185.9) compared to -20.3 ml decline with placebo 1
  • This represents a potential 118.7 ml difference favoring rentosertib at 12 weeks
  • No data on mortality, disease progression, or longer-term outcomes were reported 1

Comparison to Approved Therapies

The 2022 ATS/ERS/JRS/ALAT guidelines establish nintedanib and pirfenidone as the only evidence-based antifibrotic therapies for IPF 2. These agents have:

  • Multiple phase 3 trials with 52-week follow-up
  • Demonstrated slowing of FVC decline (nintedanib: 107-125 ml/year benefit) 2
  • Established safety profiles with known adverse event management strategies
  • Conditional recommendations from major guideline bodies 2

Rentosertib's 12-week phase 2a data cannot be compared to these established therapies given the vastly different study durations, sample sizes, and outcome certainty.

Critical Gaps in Evidence

  1. No phase 3 data: Rentosertib requires large-scale confirmatory trials before approval consideration
  2. Short duration: 12 weeks is insufficient to assess meaningful clinical outcomes in IPF, which progresses over years
  3. No mortality or progression data: The trial did not report on patient-centered outcomes prioritized by guidelines 1
  4. Liver toxicity signal: Hepatotoxicity leading to discontinuation requires careful evaluation in larger populations 1

Clinical Implications

For current practice: Rentosertib should not be used outside of clinical trials. The 2022 IPF guidelines make no mention of rentosertib, as it did not exist in the evidence base 2.

Standard of care remains:

  • Nintedanib (conditional recommendation for IPF and progressive pulmonary fibrosis after failed standard management) 2
  • Pirfenidone (conditional recommendation with 62% committee support, though 38% abstained citing insufficient evidence) 2

A recent 2026 network meta-analysis noted rentosertib showed "statistical probability of benefit" for FVC preservation but emphasized this ranking is based on "low-certainty indirect comparisons" and that "comparative effects on progression, mortality, and safety remain uncertain due to sparse data" 3.

Future Outlook

Rentosertib represents an innovative AI-discovered therapeutic approach targeting TNIK, a novel pathway in fibrosis 1. However, the path from phase 2a to approval typically requires 3-5 additional years of phase 2b/3 trials, regulatory review, and post-marketing surveillance.

The trial investigators themselves concluded that results "warrant further investigation in larger-scale clinical trials of longer duration" 1—explicitly acknowledging that rentosertib is not ready for clinical use.

Common Pitfall to Avoid

Do not confuse "AI-discovered" or "first-in-class" designations with clinical readiness. Novel mechanisms require the same rigorous evidence standards as traditional drug development. The FDA drug label evidence provided 4 pertains to Orenitram (treprostinil) for pulmonary arterial hypertension—an entirely different condition—and has no relevance to rentosertib or IPF.

References

Related Questions

In adults with idiopathic pulmonary fibrosis, should I start nerandomilast monotherapy or use dual therapy with an antifibrotic such as pirfenidone or nintedanib?
How important is it to start antifibrotic therapy when fibrous tissue is identified on a chest CT, and is early initiation essential?
What are the indication criteria for initiating nerandomilast in adult patients (≥18 years) with idiopathic pulmonary fibrosis or other chronic interstitial lung disease showing progressive fibrosis despite optimal therapy?
For an adult with progressive pulmonary sarcoidosis, which antifibrotic is preferred, Jascayd (nerandomilast) or Ofev (nintedanib)?
What are the side effects of nerandomilast (Jascayd)?
Can hepatitis B vaccine and 20-valent pneumococcal conjugate vaccine (PCV20) be administered concurrently?
In a 49-year-old man with a history of colon cancer, what core body temperature threshold indicates concern for cerebral edema?
What is the interpretation of the liver function test results showing total bilirubin 0.9 mg/dL, direct bilirubin 0.3 mg/dL, AST 61 U/L, ALT 142 U/L, alkaline phosphatase 178 U/L, albumin 3.6 g/dL, and globulin 3.1 g/dL?
What is the appropriate medication treatment for hyperthyroidism-associated forgetfulness?
What is the recommended dosing and administration schedule for nivolumab 480 mg plus relatlimab 160 mg in patients aged ≥12 years, weighing ≥40 kg, with unresectable or metastatic melanoma?
I have tongue sores while being treated for hyperthyroidism with methimazole; what are the possible causes and appropriate treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.